SWA1211

The goal of this phase I, first-in-human, open-label study is to evaluate the safety, tolerability, PK, and preliminary anti-tumor activity of SWA1211 in subjects with advanced solid tumors. It includes a Phase Ia dose escalation study and a Phase Ib dose expansion study. The main questions it aims to answer are:
1. Assess the safety and tolerability of SWA1211 in subjects with advanced solid tumors.
2. Identify the dose-limiting toxicity (DLT) to establish the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or the recommended Phase II dose (RP2D) of SWA1211.
3. Assess the PK characteristics of SWA1211.
4. Evaluate the preliminary anti-tumor activity of SWA1211.